Adrenal Incidentalomas: Contemporary Evaluation Strategies

Abstract

Adrenal incidentalomas are adrenal masses incidentally discovered during imaging performed for unrelated reasons. Their increasing prevalence, largely due to widespread use of high-resolution imaging modalities, has raised significant clinical challenges regarding optimal evaluation, risk stratification, and management. This review synthesizes current evidence and guidelines, focusing on epidemiology, pathophysiology, risk factors, clinical presentation, diagnostic evaluation, management strategies, and recent advances in the field, with emphasis on mechanism-based and clinically relevant insights for healthcare professionals.

Introduction

Adrenal incidentalomas represent a spectrum of adrenal masses detected unintentionally during radiological investigations performed for non-adrenal indications. The clinical significance of these lesions hinges on their potential to harbor malignancy or to be hormonally active, necessitating a nuanced and evidence-based approach to evaluation and management. The rising incidence, driven by improved imaging technology, mandates that clinicians remain abreast of evolving diagnostic algorithms and management paradigms to optimize patient care and outcomes.

Epidemiology / Disease Burden

The prevalence of adrenal incidentalomas has escalated over recent decades, paralleling the increased use of cross-sectional imaging. Population-based studies estimate a prevalence of 1-7% in adults, with rising rates observed in the elderly population, reaching up to 10% in those over 70 years. Most incidentally discovered lesions are benign, non-functioning adrenocortical adenomas; however, a clinically meaningful proportion warrant further evaluation for hormonal activity or malignancy. This epidemiological trend underscores the growing burden on healthcare systems and the need for standardized evaluation protocols.

Pathophysiology

Adrenal incidentalomas encompass a heterogeneous group of lesions, including benign adenomas, adrenocortical carcinomas, pheochromocytomas, myelolipomas, cysts, and metastases. The pathophysiology varies according to the underlying histology. Benign non-functioning adenomas typically result from clonal proliferation of adrenocortical cells, while hormonally active lesions can secrete cortisol (causing subclinical or overt Cushing's syndrome), aldosterone (Conn's syndrome), or catecholamines (pheochromocytoma). Malignant lesions, including primary adrenocortical carcinoma or metastatic disease, arise through complex molecular pathways involving oncogene activation and tumor suppressor gene inactivation.

Risk Factors

Risk factors for adrenal incidentalomas include advanced age, hypertension, obesity, metabolic syndrome, history of malignancy, and certain genetic syndromes (e.g., multiple endocrine neoplasia, Li-Fraumeni syndrome). Age-related adrenal cortical nodular hyperplasia is a recognized substrate for incidentaloma formation. In patients with cancer history, the likelihood of adrenal metastasis increases, particularly in lung, breast, and renal malignancies.

Clinical Features

By definition, adrenal incidentalomas are asymptomatic at discovery. However, occult hormonal hypersecretion may result in subtle clinical features such as hypertension, glucose intolerance, osteopenia, or unexplained weight gain. Classic syndromic presentations (e.g., overt Cushing's or pheochromocytoma) are uncommon in the incidentaloma context. Careful clinical assessment for subtle signs of hormone excess and a thorough review of patient history are critical components of evaluation.

Diagnosis

Diagnostic evaluation of adrenal incidentalomas aims to determine hormonal activity and malignancy risk. Biochemical screening includes tests for autonomous cortisol secretion (overnight dexamethasone suppression test), pheochromocytoma (plasma free or urinary fractionated metanephrines), and aldosteronism (plasma aldosterone-renin ratio in hypertensive or hypokalemic patients). Imaging assessment utilizes unenhanced computed tomography (CT) to characterize lesion size, morphology, and attenuation. Lesions <10 Hounsfield units (HU) on unenhanced CT are highly suggestive of benign adenomas, while higher attenuation, irregular margins, and size >4 cm raise suspicion for malignancy. Magnetic resonance imaging (MRI) and positron emission tomography (PET) may be employed in indeterminate cases. Fine-needle aspiration is reserved for selected cases, typically when metastatic disease is suspected in patients with a known extra-adrenal malignancy and after pheochromocytoma has been excluded biochemically.

Treatment & Management

Management strategies are guided by lesion size, imaging characteristics, and hormonal activity. Non-functioning lesions <4 cm with benign imaging features can be monitored with periodic imaging and clinical follow-up. Surgical resection is indicated for hormonally active tumors, lesions with suspicious imaging features, or those >4-6 cm due to increased malignancy risk. Laparoscopic adrenalectomy is the preferred approach for benign-appearing, localized lesions. Multidisciplinary evaluation is essential for malignant or indeterminate masses, with consideration of oncologic management and individualized risk assessment. Patient comorbidities, surgical risk, and preferences must be integrated into the decision-making process.

Recent Advances / Emerging Therapies

Recent advances include the development of advanced imaging techniques (e.g., CT washout protocols, chemical shift MRI), improved molecular profiling, and the integration of artificial intelligence for risk stratification. Noninvasive biomarkers of malignancy and hormone secretion are under investigation. Minimally invasive surgical approaches have evolved, and ablation techniques are being explored for selected cases. Ongoing research into the genetic and molecular underpinnings of adrenocortical tumors holds promise for targeted therapies and personalized management.

Guideline Recommendations

International guidelines from the Endocrine Society and European Society of Endocrinology endorse a structured approach: all patients with adrenal incidentalomas should undergo initial hormonal evaluation and imaging characterization. Repeat imaging at 6-12 months is recommended for indeterminate, non-functioning lesions <4 cm, with discontinuation of follow-up if stability is confirmed. Surgery is recommended for all functioning tumors, lesions with high-risk imaging features, and those exceeding size thresholds. Shared decision-making and patient-centered care are emphasized, with tailored management for high-risk populations.

Conclusion

Adrenal incidentalomas present a growing clinical challenge, necessitating systematic evaluation to balance the risks of malignancy and hormone excess against overtreatment. Contemporary strategies integrate imaging, biochemical assessment, and individualized management in accordance with evidence-based guidelines. Ongoing research and technological advances continue to refine risk stratification and therapeutic approaches, underscoring the importance of multidisciplinary collaboration in optimizing patient outcomes.